Pay in 4 interest-free payments of $5.16 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Similar content being viewed by others Introduction Ovarian cancer is the most lethal gynecologic malignancy, with a dismal 50% 5-year survival rate, primarily due to late-stage diagnosis and aggressive tumor biology 1,2
Brighten: Fantastic
Might have some weak anti-oxidant properties Total Promises Fulfilled score: 87 /100
Available through the member portal under "Coverage Decisions" Provides a binding answer before you fill the prescription Turnaround time is 72 hours for standard requests Step 5: Check for manufacturer copay assistance eligibility
In a letter (PDF) to shareholders, executives said the company has a legal pathway to sell "personalized titration schedules and dosage levels that are not essentially copies of commercially available medications" that allow providers to "meet the needs of individual patients regardless of shortage dynamics." Hims & Hers said revenue from its non-GLP-1 offerings totaled $1.2 billion of the $1.48 billion that it brought in last year, suggesting the company sold roughly $200 million in compounded GLP-1 drugs last year
On GLP-1s, that guidance matters even more
